Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
THRD Third Harmonic Bio
- 5.160
- +0.010+0.19%
Trading Apr 24 12:36 ET
232.74MMarket Cap4.73P/E (TTM)
5.160High5.140Low50.77KVolume5.140Open5.150Pre Close261.67KTurnover0.33%Turnover Ratio4.73P/E (Static)45.10MShares16.94052wk High0.82P/B79.45MFloat Cap3.18052wk Low--Dividend TTM15.40MShs Float24.595Historical High--Div YieldTTM0.39%Amplitude3.180Historical Low5.153Avg Price1Lot Size
About Third Harmonic Bio Company
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Company Profile
SymbolTHRD
Company NameThird Harmonic Bio
Listing DateSep 15, 2022
Issue Price17.00
Founded2019
CEOMs. Natalie C. Holles
MarketNASDAQ
Employees53
Fiscal Year Ends12-31
Address1700 Montgomery Street,Suite 210
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94111
Phone1-209-727-2457
Websitehttp://thirdharmonicbio.com
Company Executives
- Name
- Position
- Salary
- Natalie C. Holles
- Chief Executive Officer and Director
- 2.54M
- Julie Person
- Chief Administrative Officer
- 1.11M
- Dr. Edward R. Conner, M.D.
- Chief Medical Officer
- 1.38M
- Christopher M. Murphy
- Treasurer, Principal Accounting Officer, Chief Financial and Business Officer
- --
- Mark T. Iwicki
- Chairman of the Board
- 174.62K
- Robert J. Perez
- Independent Director
- 62.71K
- Dr. Geoffrey McDonough, M.D.
- Independent Director
- --
- Thomas M. Soloway
- Independent Director
- 172.85K
- Michael Gladstone
- Independent Director
- 119.84K
- Dr. H. Martin Seidel, PhD
- Independent Director
- 130.04K
- Dr. Geoff McDonough
- Independent Director
- --
- Dr. David P. Bonita, M.D.
- Independent Director
- 119.84K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
